02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

530 TESTOLACTONE<br />

TESTOLACTONE<br />

Synonym: delta-1-testolactone<br />

Trade name: Teslac (Bristol-Myers Squibb)<br />

Indications: Advanced disseminated breast carcinoma<br />

Category: Androgen; Antineoplastic; Aromatase inhibitor<br />

Half-life: N/A<br />

Clinically important, potentially hazardous interactions<br />

with: anticoagulants<br />

Reactions<br />

Skin<br />

Angioedema<br />

Exanthems<br />

Peripheral edema<br />

Mucosal<br />

Glossitis<br />

Hair<br />

Hair – alopecia<br />

Other<br />

Abdominal pain<br />

(1993): Feuillan PP+, J Clin Endocrinol Metab 77(3), 647<br />

TESTOSTERONE<br />

Trade names: Andro-L.A; Androderm (Watson); AndroGel<br />

(Unimed); Andronaq; Delatest; Delatestryl (Savient); depAndro;<br />

Duratest; Malogen; Test<strong>and</strong>ro; Testex; Testim (Auxilium);<br />

Testoderm (Ortho-McNeil); Testopel<br />

Indications: Androgen replacement, hypogonadism, postpartum<br />

breast pain<br />

Category: Androgen<br />

Half-life: 10–100 minutes<br />

Clinically important, potentially hazardous interactions<br />

with: anisindione, anticoagulants, cyclosporine, dicumarol,<br />

warfarin<br />

Reactions<br />

Skin<br />

Acne (>10%)<br />

(2006): Kalantaridou SN+, Semin Reprod Med 24(2), 106<br />

(1998): Kwon PS+, Arch Dermatol 134, 376<br />

(1995): Tabata N+, JAmAcadDermatol33, 676 (infantile)<br />

(1992): Fyr<strong>and</strong> O+, Acta Derm Venereol 72, 148<br />

(1990): Fuchs E+, JAmAcadDermatol23, 125<br />

(1989): Fyr<strong>and</strong> O+, Tidsskr Nor Laegeforen (Norwegian)<br />

109, 239<br />

(1989): Hartmann AA+, Monatsschr Kinderheilkd (German)<br />

137, 466<br />

(1989): Heydenreich G, Arch Dermatol 125, 571 (fulminans)<br />

(1989): Scott MJ+, Cutis 44, 30<br />

(1989): von Muhlendahl KE+, Dtsch Med Wochenschr (German)<br />

114, 712<br />

(1988): Traupe H+, Arch Dermatol 124, 414 (fulminans)<br />

(1987): Kiraly CL+, Am J Dermatopathol 9, 515<br />

(1984): Lamb DR, Am J Sports Med 12, 31<br />

Carcinoma<br />

(2006): Dizon DS+, Gynecol Obstet Invest 62(4), 226 (ovarian)<br />

Dermatitis (4%)<br />

(1998): Buckley DA+, Contact Dermatitis 39, 91 (from patch)<br />

(1989): Holdiness MR, Contact Dermatitis 20, 3 (from patch)<br />

Edema (1–10%)<br />

Exanthems<br />

(2001): McGriff NJ+, Pharmacotherapy 21(11), 1425<br />

Folliculitis<br />

(1998): Kwon PS+, Arch Dermatol 134, 376<br />

Furunculosis<br />

(1989): Scott MJ+, Cutis 44, 30<br />

Lichenoid eruption<br />

(1989): Aihara M+, JDermatol(Tokio) 16, 330<br />

Lupus erythematosus<br />

Peripheral edema<br />

Pruritus<br />

(2001): McGriff NJ+, Pharmacotherapy 21(11), 1425<br />

Psoriasis<br />

(1990): O’Driscoll JB+, Clin Exp Dermatol 15, 68<br />

Rash (sic) (2%)<br />

Seborrhea (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!